Keryx Biopharmaceuticals Inc.
http://www.keryx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Keryx Biopharmaceuticals Inc.
Midatech Survival Plan Scuppered By Shareholders
The UK firm's shareholders have not approved plans to acquire Bioasis, a decision that puts Midatech in a tricky situation as its cash will run out by mid-March.
Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
Chiesi Expands Its Rare Disease Reach With $1.48bn Amryt Buyout
The privately owned company currently earns most of its revenues in respiratory medicine in Europe, but has set its sights on expanding in rare diseases and the US market.
Nichi-Iko Secures Up To ¥98.5bn Debt Relief As ADR Pushes Ahead
Troubled Japanese firm Nichi-Iko has currently has ¥55.8bn of debt forgiveness, which may expand to ¥98.5bn in the future. It currently faces regular payments until 2033 to settle all of its debts.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Access Oncology
- AOI Pharma, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice